51 results
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
9 May 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
6:37am
-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
27 Feb 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
6:38am
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including
8-K
NUVL
Nuvalent Inc - Ordinary Shares
9 Jan 24
Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones
4:40pm
on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including
8-K
EX-99.1
4nwjlnx8j
9 Jan 24
Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones
4:40pm
8-K
EX-99.1
haz9hnvm
14 Nov 23
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter
6:45am
8-K
EX-99.1
wlw129koayu6
17 Oct 23
Nuvalent Announces Pricing of Public Offering of Common Stock
4:07pm
424B5
y628 5hah
17 Oct 23
Prospectus supplement for primary offering
4:05pm
424B5
hrekyjvfqpym
16 Oct 23
Prospectus supplement for primary offering
7:39am
8-K
tptdht5
13 Oct 23
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
6:40am
8-K
EX-99.1
4kgz6qkl jnh6s
13 Oct 23
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
6:40am
8-K
EX-99.1
os4gwmcmrnjnf0to
4 Oct 23
Other Events
4:05pm
8-K
29paqmiq86cp0e1xt
4 Oct 23
Other Events
4:05pm
8-K
EX-99.1
khtvbpet4ntwqqczi0zr
10 Aug 23
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
6:45am
8-K
EX-99.1
esvtuhn 47ayv9kv1l
11 May 23
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
6:39am